SCHEMBL1765240

SCHEMBL1765240

Fc1cccc(F)c1C1CCCCN1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C19 P33261 2/20 0.46
KMT2A Q03164 2/20 0.46
CHRNB2 P17787 2/20 0.46
CHRNA7 P36544 2/20 0.46
CHRNA4 P43681 2/20 0.46
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CHRM5 P08912 3/20 0.41
CHRM3 P20309 3/20 0.41
CHRM1 P11229 2/20 0.41
CHRM2 P08172 2/20 0.41
CHRM4 P08173 2/20 0.41
ABCB1 P08183 1/20 0.40
HTR1A P08908 1/20 0.38
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29589051 0.94 CHRM5 (0.46) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL20575902 0.94 CHRM5 (0.46) MEN1CYP2D6CYP2C19KMT2ACHRNB2
Hydrochloric Acid SCHEMBL31444377 0.92 CHRM5 (0.44) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL24774560 0.82 KMT2A (0.42) MEN1KMT2ACHRNB2CHRNA7CHRNA4
SCHEMBL31198384 0.81 CHRNB2 (0.45) MEN1KMT2ACHRNB2CHRNA7CHRNA4
SCHEMBL31444475 0.80 MEN1 (0.42) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL1764675 0.79 KDM4E (0.46) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL30812563 0.79 KDM4E (0.46) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL30008129 0.79 KDM4E (0.46) MEN1CYP2D6CYP2C19KMT2ACHRNB2
SCHEMBL31444396 0.79 OPRL1 (0.43) MEN1CYP2D6CYP2C19KMT2ACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102753538-B Sultam derivatives HOFFMANN LA ROCHE 2015-04-08 CN disclosed
EP-2504324-B1 SULTAM DERIVATIVES HOFFMANN LA ROCHE (CH) 2015-02-25 EP disclosed
US-8314250-B2 Sultam derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-20 US disclosed
EP-2504324-A1 SULTAM DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-03 EP disclosed
WO-2011064141-A1 SULTAM DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-03 WO disclosed
US-20110124686-A1 SULTAM DERIVATIVES ANDERSON KEVIN W 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124686-A1 SULTAM DERIVATIVES SULT1A1, SULT2A1, SULT1E1 MEN1 3823/4885CYP2D6 65/4885CYP2C19 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.